Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 12:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoarthritis of the Knee or Hip Clear all
Completed Phase 2Phase 3 Interventional

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

NCT02447276
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
REGN475, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 25, 2026, 12:56 PM EDT
Terminated Phase 2 Interventional

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

NCT00973141
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

NCT02336698
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Costa Mesa, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Jul 25, 2026, 12:56 PM EDT
Recruiting Not applicable Interventional

Outcomes of Low-Impact Exercise Program for People With Ankle, Knee, and/or Hip Pain

NCT03711773
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Ankle
Interventions
Group Physical Therapy Classes
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 1 Interventional

To Assess the Patients' Ability to Self-Administer Fasinumab

NCT03491904
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab AI, Fasinumab PFS
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Jul 25, 2026, 12:56 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NCT00994890
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
100
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 4 Interventional Results available

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

NCT00139776
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Celecoxib
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
67
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jul 25, 2026, 12:56 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip

NCT00809354
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
NSAID, tanezumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
250
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 161 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Not applicable Interventional

Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement

NCT01373099
View directory record Official record
Conditions
Osteoarthritis, Hip Infection, Prosthetic Joint Infection, Complications; Arthroplasty, Infection or Inflammation, Complications; Arthroplasty
Interventions
Implantation of a static, non-articulating cement spacer., Implantation of an articulating spacer.
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

NCT00314652
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional Results available

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

NCT01141283
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 25, 2026, 12:56 PM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

NCT02528188
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
299
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional

Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)

NCT01722864
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Low Back Pain
Interventions
COV155
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Anaheim, California • Lomita, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

NCT02301234
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Celecoxib 100 mg, Celecoxib 100 mg Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

NCT02944448
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Knee, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
CR845 tablet 1 mg, CR845 tablet 2.5 mg, CR845 tablet 5 mg, Placebo tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 25, 2026, 12:56 PM EDT
Completed No phase listed Observational

An Analysis of the Outcomes From Protocolized Perioperative Care for Patients Receiving Total Hip or Knee Arthroplasty

NCT03071250
View directory record Official record
Conditions
Knee Osteoarthritis, Hip Osteoarthritis, Knee Arthritis, Hip Arthritis
Interventions
Total knee or Hip Arthroplasty
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03304379
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Diclofenac, Celecoxib, Matching placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

NCT03691974
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 25, 2026, 12:56 PM EDT
Completed Phase 3 Interventional Results available

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

NCT01094886
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions
Rivaroxaban
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jul 25, 2026, 12:56 PM EDT